- SEK43.76m
- SEK37.92m
Brief: Combigene: Shareholder Proposes Luca Di Stefano As Chairman
Brief: Combigene Q3 Loss From Financial Items SEK 9.0 Mln
Brief: Combigene Q3 Sales SEK 0
Brief: Combigene Terminates CG01 Epilepsy Program, Implements Cost Reduction
Brief: Combigene - New Preclinical Research Results In Epilepsy Project
Brief: Combigene Q2 Sales SEK 0
Brief: Combigene Enters Into License Agreement With Spark
Brief: Combigene Q1 Sales SEK 326 Thousand
Brief: Combigene: Epilepsy Project CG01 Granted Patent In Two New Countries
Brief: Orphazyme Acquires 10% Of Shares In CombiGene
Brief: Combigene Q4 Loss Before Depreciation Narrows To SEK 8.6 Mln
Brief: Combigene Q4 Sales SEK 596 Thousand
Brief: Combigene Discontinues Preclinical Development Of Lipodystrophy Project CGT2
Brief: Combigene Says Eurostars Contributes SEK 8.7 Mln To Financing Of Project
Brief: Combigene Q3 Net Sales Down At SEK 992,000
Brief: Combigene Q3 EPS SEK -0.42
Brief: Combigene Chooses Charles River As Preclinical Toxicology Partner For COZY01 Pain Project
Brief: Spark Therapeutics Ends Agreement With Combigene
Brief: CombiGene Chooses CDMO Partner For COZY01 Pain Project